Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Research powered by GOALZEN CAPITAL SERVICES PRIVATE LIMITED · SEBI Research Analyst INH000013448
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
3
Neutral
3
Bullish
8
Bearish
35
Neutral
3
Bullish
8
Bearish
32
Neutral
0
Bullish
0
Bearish
3
Neutral
3
Bullish
8
Bearish
3
Neutral
3
Bullish
8
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Discovery themes featuring this stock
Anuh Pharma is a publicly listed Indian manufacturer of Active Pharmaceutical Ingredients (APIs), specialising in macrolides, anti-TB molecules, corticosteroids and other therapeutic categories, operating a DSIR-accredited R&D centre and a Tarapur manufacturing complex with nine API blocks totalling 2,400 MTPA capacity, serving over 72 countries via ~360 marketing partners.
Q1 FY27 financials show operating revenue of Rs.193.81 crore (+3.9% YoY) while profitability expanded much faster: EBITDA grew 41.6% to Rs.19.36 crore (9.99% margin) and PAT jumped 37.6% to Rs.11.42 crore, driven by a richer product mix, disciplined cost control and improved throughput that lifted ROCE to 19.18%.
Anuh Pharma has demonstrable regulatory credentials with recent USFDA and EU GMP clearances, multiple EDQM CEPs and WHO pre-qualifications across its portfolio; these approvals underpin management’s strategy to prioritise regulated-market sales and supported approximately 46% of FY26 revenues from exports, enhancing the company’s pricing and customer diversification potential.
The company is debt-free with a consistent dividend record, operates a Zero Liquid Discharge system and 100% power backup at Tarapur for compliance advantage, and guides for a steady 15–20% annual growth driven by higher-value regulated-market penetration and a product pipeline including Pretomanid, Edoxaban tosylate and Bisoprolol fumarate.
Pharmaceuticals & Biotechnology
Pharmaceuticals
771 Cr
Low Risk
17.5
34.8
4.1
2.2
99.50
67.00
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
491.50 | 843 Cr | 106.03 | 36.11 | 0.00 | 27.97 | 29.48 | 14.57 | ||
90.35 | 832 Cr | 20.82 | 2.27 | 0.55 | 0.42 | 2.70 | 6.68 | ||
625.70 | 803 Cr | 52.02 | 4.93 | 0.00 | 10.90 | 14.23 | 7.43 | ||
76.63 | 771 Cr | 17.45 | 2.19 | 1.95 | 11.65 | 15.53 | 7.92 | ||
61.57 | 757 Cr | 21.10 | 2.62 | 0.00 | 16.26 | 20.71 | 12.42 | ||
202.24 | 711 Cr | 24.36 | 2.54 | 0.00 | 10.79 | 12.00 | 6.38 | ||
129.25 | 702 Cr | 43.87 | 2.26 | 0.00 | -1.05 | 0.74 | 3.45 | ||
| Median: 7 Co. | — | 129.25 | 771 Cr | 24.36 | 2.54 | 0.00 | 10.90 | 14.23 | 7.43 |
Anuh Pharma Ltd (ANUHPHR) is currently trading at 76.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Anuh Pharma is a publicly listed Indian manufacturer of Active Pharmaceutical Ingredients (APIs), specialising in macrolides, anti-TB molecules, corticosteroids and other therapeutic categories, operating a DSIR-accredited R&D centre and a Tarapur manufacturing complex with nine API blocks totalling 2,400 MTPA capacity, serving over 72 countries via ~360 marketing partners. Q1 FY27 financials show operating revenue of Rs.193.81 crore (+3.9% YoY) while profitability expanded much faster: EBITDA grew 41.6% to Rs.19.36 crore (9.99% margin) and PAT jumped 37.6% to Rs.11.42 crore, driven by a richer product mix, disciplined cost control and improved throughput that lifted ROCE to 19.18%. Anuh Pharma has demonstrable regulatory credentials with recent USFDA and EU GMP clearances, multiple EDQM CEPs and WHO pre-qualifications across its portfolio; these approvals underpin management’s strategy to prioritise regulated-market sales and supported approximately 46% of FY26 revenues from exports, enhancing the company’s pricing and customer diversification potential. The company is debt-free with a consistent dividend record, operates a Zero Liquid Discharge system and 100% power backup at Tarapur for compliance advantage, and guides for a steady 15–20% annual growth driven by higher-value regulated-market penetration and a product pipeline including Pretomanid, Edoxaban tosylate and Bisoprolol fumarate.
Over the past 52 weeks, Anuh Pharma Ltd has traded between a low of ₹67.00 and a high of ₹99.50. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Anuh Pharma Ltd has a market capitalization of approximately 770.72. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Anuh Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 17.45 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 770.72 Cr, Anuh Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Anuh Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Anuh Pharma Ltd is 17.45. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Standalone revenue from operations was ₹193.81 crore and net profit after tax was ₹11.42 crore for the quarter ended 30 June 2026.
The board meeting is scheduled for May 20, 2026.
FY26 revenue from operations was ₹77,165.74 lakh and FY26 net profit was ₹4,104.61 lakh, as per the audited results disclosed.
The provided text states a board meeting is scheduled on 06/02/2026 to consider and approve unaudited financial results along with a limited review report.
